GAPDH is recognized as a novel autoantigen associated with neuropsychiatric disorders, and research by Delunardo et al. uncovered a significant positive correlation between serum anti-GAPDH antibodies levels and harmful cognition and mood (e.g., schizophrenia and major depression) in SLE patients. This evidence concerns the gene GAPDH and schizophrenia.